Moderately severe acute pancreatitis: Prospective validation of this new subgroup of acute pancreatitis

Rupjyoti Talukdar, Magdalen Clemens, Santhi Swaroop Vege

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

OBJECTIVE: We described the entity moderately severe acute pancreatitis (MSAP), characterized by local complications (LCs) without organ failure (OF). The aim of this study was to validate MSAP. METHODS: We classified a prospectively collected cohort of 137 acute pancreatitis patients admitted to Mayo Clinic Hospitals into (a) severe acute pancreatitis (SAP; n = 15), presence of OF with/without LCs; (b) MSAP (n = 27), presence of LCs without OF; and (c) mild acute pancreatitis (MAP; n = 95), no OF and LCs. Primary outcomes were need for intensive care unit (ICU) care, total ICU days, total hospital stay, need for interventions, and death. RESULTS: Scores in the Acute Physiology and Chronic Health Evaluation II during admission were significantly different among the 3 groups (MAP vs MSAP, P = 0.02; MSAP vs SAP, P = 0.001); scores in the systemic inflammatory response syndrome during admission were similar between MAP and MSAP. Compared with patients with MAP, patients with MSAP had a significantly longer hospital stay (4 [3.0-7.0] vs 6 [4.0-18.0] days). Compared with those with SAP, a significantly smaller proportion of patients with MSAP required ICU care (12% vs 80%); total hospital stay and need for interventions were similar (6 [4.0-18.0] vs 21 [11.8-27] days and 44% vs 33%, respectively). None of the MSAP patients died compared with 40% from the SAP group. CONCLUSIONS: We have validated MSAP as an exclusive entity.

Original languageEnglish (US)
Pages (from-to)306-309
Number of pages4
JournalPancreas
Volume41
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Pancreatitis
Intensive Care Units
Length of Stay
Systemic Inflammatory Response Syndrome
APACHE

Keywords

  • local complications
  • moderately severe acute pancreatitis
  • necrosis
  • peripancreatic collections
  • prospective study
  • validation study

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Moderately severe acute pancreatitis : Prospective validation of this new subgroup of acute pancreatitis. / Talukdar, Rupjyoti; Clemens, Magdalen; Vege, Santhi Swaroop.

In: Pancreas, Vol. 41, No. 2, 03.2012, p. 306-309.

Research output: Contribution to journalArticle

@article{aa3cdb364af041179092fd25dcb89033,
title = "Moderately severe acute pancreatitis: Prospective validation of this new subgroup of acute pancreatitis",
abstract = "OBJECTIVE: We described the entity moderately severe acute pancreatitis (MSAP), characterized by local complications (LCs) without organ failure (OF). The aim of this study was to validate MSAP. METHODS: We classified a prospectively collected cohort of 137 acute pancreatitis patients admitted to Mayo Clinic Hospitals into (a) severe acute pancreatitis (SAP; n = 15), presence of OF with/without LCs; (b) MSAP (n = 27), presence of LCs without OF; and (c) mild acute pancreatitis (MAP; n = 95), no OF and LCs. Primary outcomes were need for intensive care unit (ICU) care, total ICU days, total hospital stay, need for interventions, and death. RESULTS: Scores in the Acute Physiology and Chronic Health Evaluation II during admission were significantly different among the 3 groups (MAP vs MSAP, P = 0.02; MSAP vs SAP, P = 0.001); scores in the systemic inflammatory response syndrome during admission were similar between MAP and MSAP. Compared with patients with MAP, patients with MSAP had a significantly longer hospital stay (4 [3.0-7.0] vs 6 [4.0-18.0] days). Compared with those with SAP, a significantly smaller proportion of patients with MSAP required ICU care (12{\%} vs 80{\%}); total hospital stay and need for interventions were similar (6 [4.0-18.0] vs 21 [11.8-27] days and 44{\%} vs 33{\%}, respectively). None of the MSAP patients died compared with 40{\%} from the SAP group. CONCLUSIONS: We have validated MSAP as an exclusive entity.",
keywords = "local complications, moderately severe acute pancreatitis, necrosis, peripancreatic collections, prospective study, validation study",
author = "Rupjyoti Talukdar and Magdalen Clemens and Vege, {Santhi Swaroop}",
year = "2012",
month = "3",
doi = "10.1097/MPA.0b013e318229794e",
language = "English (US)",
volume = "41",
pages = "306--309",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Moderately severe acute pancreatitis

T2 - Prospective validation of this new subgroup of acute pancreatitis

AU - Talukdar, Rupjyoti

AU - Clemens, Magdalen

AU - Vege, Santhi Swaroop

PY - 2012/3

Y1 - 2012/3

N2 - OBJECTIVE: We described the entity moderately severe acute pancreatitis (MSAP), characterized by local complications (LCs) without organ failure (OF). The aim of this study was to validate MSAP. METHODS: We classified a prospectively collected cohort of 137 acute pancreatitis patients admitted to Mayo Clinic Hospitals into (a) severe acute pancreatitis (SAP; n = 15), presence of OF with/without LCs; (b) MSAP (n = 27), presence of LCs without OF; and (c) mild acute pancreatitis (MAP; n = 95), no OF and LCs. Primary outcomes were need for intensive care unit (ICU) care, total ICU days, total hospital stay, need for interventions, and death. RESULTS: Scores in the Acute Physiology and Chronic Health Evaluation II during admission were significantly different among the 3 groups (MAP vs MSAP, P = 0.02; MSAP vs SAP, P = 0.001); scores in the systemic inflammatory response syndrome during admission were similar between MAP and MSAP. Compared with patients with MAP, patients with MSAP had a significantly longer hospital stay (4 [3.0-7.0] vs 6 [4.0-18.0] days). Compared with those with SAP, a significantly smaller proportion of patients with MSAP required ICU care (12% vs 80%); total hospital stay and need for interventions were similar (6 [4.0-18.0] vs 21 [11.8-27] days and 44% vs 33%, respectively). None of the MSAP patients died compared with 40% from the SAP group. CONCLUSIONS: We have validated MSAP as an exclusive entity.

AB - OBJECTIVE: We described the entity moderately severe acute pancreatitis (MSAP), characterized by local complications (LCs) without organ failure (OF). The aim of this study was to validate MSAP. METHODS: We classified a prospectively collected cohort of 137 acute pancreatitis patients admitted to Mayo Clinic Hospitals into (a) severe acute pancreatitis (SAP; n = 15), presence of OF with/without LCs; (b) MSAP (n = 27), presence of LCs without OF; and (c) mild acute pancreatitis (MAP; n = 95), no OF and LCs. Primary outcomes were need for intensive care unit (ICU) care, total ICU days, total hospital stay, need for interventions, and death. RESULTS: Scores in the Acute Physiology and Chronic Health Evaluation II during admission were significantly different among the 3 groups (MAP vs MSAP, P = 0.02; MSAP vs SAP, P = 0.001); scores in the systemic inflammatory response syndrome during admission were similar between MAP and MSAP. Compared with patients with MAP, patients with MSAP had a significantly longer hospital stay (4 [3.0-7.0] vs 6 [4.0-18.0] days). Compared with those with SAP, a significantly smaller proportion of patients with MSAP required ICU care (12% vs 80%); total hospital stay and need for interventions were similar (6 [4.0-18.0] vs 21 [11.8-27] days and 44% vs 33%, respectively). None of the MSAP patients died compared with 40% from the SAP group. CONCLUSIONS: We have validated MSAP as an exclusive entity.

KW - local complications

KW - moderately severe acute pancreatitis

KW - necrosis

KW - peripancreatic collections

KW - prospective study

KW - validation study

UR - http://www.scopus.com/inward/record.url?scp=84857912952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857912952&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e318229794e

DO - 10.1097/MPA.0b013e318229794e

M3 - Article

C2 - 22015971

AN - SCOPUS:84857912952

VL - 41

SP - 306

EP - 309

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -